Tvardi Therapeutics is trading at $1.38, up 10.51%, with the October 1 pre-market gain’s cause unclear. - No clear company-specific announcement or catalyst explaining the move surfaced in the search. - The latest company press-release listing found was dated September 24. - Broader markets were modestly higher, but available context does not establish that this explains the stock’s gain.